Rethinking GLP-1s: Balancing Benefits, Budgets, and Long-Term Health

This 2025 report explores the rapid rise in demand for GLP-1 receptor agonists—medications originally used to treat diabetes, now widely prescribed for weight loss and related chronic conditions.

Key Findings:

Takeaway:

GLP-1s hold promise for managing obesity and metabolic disease but present major challenges in cost, adherence, and equitable access. The report calls for comprehensive strategies combining clinical guidance, lifestyle support, and cost control to ensure sustainable use.